@article{550bd21a0a4e483aa4aecd11ef7a6c79,
title = "Preferences of adults with cancer for systemic cancer treatment: do preferences differ based on age?",
abstract = "Background: We used the Therapy Preference Scale, a 30-item questionnaire, to determine cancer treatment preferences of adults with cancer. Methods: We used Wilcoxon's rank sum test and Fisher's exact test to compare the preferences of younger (<60 years) versus older adults (≥60 years). Results: While 56% of patients would accept treatment offering increased life expectancy at an expense of short-term side effects, 75% preferred maintenance of cognition, functional ability and quality of life to quantity of days. Oral instead of intravenous treatment (p = 0.003), shorter hospital stay (p = 0.03), preservation of cognitive function (p = 0.01) and avoidance of pain (p = 0.02) were more important to older patients compared with younger patients. Conclusion: Many patients prioritized maintenance of cognition, functional ability and quality of life; older patients valued oral treatment, shorter hospital stay, preservation of cognitive function and avoidance of pain.",
keywords = "cancer, cognition, life expectancy, patients, preferences, quality of life, questionnaire, therapy, treatment",
author = "Prajwal Dhakal and Wichman, {Christopher S.} and Bunny Pozehl and Meaghann Weaver and Fisher, {Alfred L.} and Julie Vose and Bociek, {R. Gregory} and Bhatt, {Vijaya R.}",
note = "Funding Information: This work was supported in part by the National Institute of General Medical Sciences, 1 U54 GM115458, which funds the Great Plains Institutional Development Award (IDeA) Clinical Translational Research (CTR) Network. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. V Bhatt reports receiving consulting fees from Genentech, Rigel, Agios, Incyte, Omeros, Takeda, Partnership for health analytic research, LLC (which in turn, receives funds from Jazz Pharmaceuticals) and Abbvie; research funding (institutional) from Abbvie, Pfizer, Incyte, Jazz, Tolero Pharmaceuticals, Inc. and National Marrow Donor Program; and drug support (institutional) from Oncoceutics for a trial. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript. Publisher Copyright: {\textcopyright} 2021 Future Medicine Ltd.",
year = "2022",
month = jan,
doi = "10.2217/fon-2021-0260",
language = "English (US)",
volume = "18",
pages = "311--321",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "3",
}